|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:approves
|
gptkb:2006
gptkb:FDA
|
|
gptkbp:associated_with
|
gptkb:skincare_product
menstrual cycle regulation
endometriosis treatment
polycystic ovary syndrome management
premenstrual syndrome relief
|
|
gptkbp:brand
|
gptkb:Loestrin
|
|
gptkbp:clinical_trial
|
studies on efficacy
studies on safety
studies on side effects
|
|
gptkbp:contains
|
gptkb:norethindrone_acetate
gptkb:ethinyl_estradiol
|
|
gptkbp:contraindication
|
liver disease
certain cancers
history of blood clots
smoking over age 35
|
|
gptkbp:dosage_form
|
combination pill
24 active tablets and 4 inactive tablets
|
|
gptkbp:duration
|
monthly
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:healthcare
|
oral tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Loestrin 24 Fe
|
|
gptkbp:ingredients
|
gptkb:norethindrone_acetate
gptkb:ethinyl_estradiol
|
|
gptkbp:interacts_with
|
gptkb:St._John's_Wort
antibiotics
anticonvulsants
HIV medications
|
|
gptkbp:is_available_in
|
gptkb:various_countries
|
|
gptkbp:is_effective_against
|
over 99% with perfect use
91% with typical use
|
|
gptkbp:is_used_for
|
birth control
|
|
gptkbp:launched
|
first day of menstrual cycle
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:marketed_as
|
gptkb:Loestrin_24_Fe
Loestrin brand
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:population
|
consult healthcare provider
report side effects
read patient leaflet
|
|
gptkbp:previous_name
|
ethinyl estradiol and norethindrone
|
|
gptkbp:regulatory_compliance
|
FDA approved
|
|
gptkbp:related_to
|
other hormonal contraceptives
|
|
gptkbp:replaced_by
|
menstrual period
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:shoots
|
once daily
|
|
gptkbp:side_effect
|
headache
nausea
weight gain
breast tenderness
mood changes
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:bfsParent
|
gptkb:norgestimate
|
|
gptkbp:bfsLayer
|
5
|